Discovery of potent and orally bioavailable benzothiazole-benzenesulfonamide derivatives as ABCA1 upregulators for the management of dyslipidemia
- 15 January 2026
- journal article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 306, 118582
Abstract
No abstract availableKeywords
Funding Information
- Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
- Hebei Provincial Natural Science Foundation (H2024205002)
- Hebei Provincial Natural Science Foundation (H2022307031)
- Hebei Provincial Department of Science and Technology (22567622H)
- Department of Science and Technology of Hubei Province
- National Natural Science Foundation of China (82404723)
- National Natural Science Foundation of China (82574403)
This publication has 31 references indexed in Scilit:
- Nonlipogenic ABCA1 Inducers (NLAI) for Alzheimer’s Disease Validated in a Mouse Model Expressing Human APOE3/APOE4Journal of Medicinal Chemistry, 2024
- A pan-PPAR agonist E17241 ameliorates hyperglycemia and diabetic dyslipidemia in KKAy mice via up-regulating ABCA1 in islet, liver, and white adipose tissueBiomedicine & Pharmacotherapy, 2024
- History and Development of ABCA1Current Problems in Cardiology, 2023
- ABCA1 DeficiencyJACC: Case Reports, 2023
- ANGPTL3 as a Drug Target in Hyperlipidemia and AtherosclerosisCurrent Atherosclerosis Reports, 2022
- ABCA1 and ABCG1 as potential therapeutic targets for the prevention of atherosclerosisJournal of Pharmacological Sciences, 2022
- Foam cell formation: A new target for fighting atherosclerosis and cardiovascular diseaseVascular Pharmacology, 2019
- Animal models of atherosclerosisEuropean Journal of Pharmacology, 2017
- Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk FactorsJACC, 2017
- Optimization of Rutaecarpine as ABCA1 Up-Regulator for Treating AtherosclerosisACS Medicinal Chemistry Letters, 2014